New Drug for Mismatch Repair Deficient Endometrial Cancer and Solid Tumors

The Food and Drug Administration (FDA) has granted accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of adults with mismatch repair deficient recurrent or advanced endometrial cancer and solid tumors.